%PDF-1.4
%
59 0 obj
<>
endobj
56 0 obj
<>
endobj
111 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-02T20:13:03Z
2024-03-28T18:39:58-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T18:39:58-07:00
application/pdf
Heather
2000-971.feb
uuid:25e027d7-1dd2-11b2-0a00-1b09275dc400
uuid:25e027d9-1dd2-11b2-0a00-810000000000
endstream
endobj
45 0 obj
<>
endobj
46 0 obj
<>
endobj
60 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
12 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
25 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
28 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
133 0 obj
[137 0 R]
endobj
134 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 57 714.5293 Tm
[(17.)-625.1 (Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH,)]TJ
0 Tc 1.875 -1.25 Td
[(and )17.7 (The Committee On Prognosis Studies In SLE Derivation of the)]TJ
0 -1.25 TD
[(SLEDAI \227 )54.8 (A)-219.8 (disease activity index for lupus patients. )54.8 (Arthritis)]TJ
T*
(Rheum 1992;35:630-40.)Tj
-1.875 -1.25 Td
[(18.)-625 (National Institutes of Health. Health implications of obesity)64.9 (.)]TJ
1.875 -1.25 Td
(National Institutes of Health consensus development conference)Tj
T*
[(statement. )54.9 (Ann Intern Med 1985;103:1073-7.)]TJ
-0.00011 Tc -1.875 -1.25 Td
[(19.)-625.1 (Castelli )17.7 (WP)110.7 (, Garrison RJ, )17.7 (W)39.7 (ilson PW)91.7 (, )54.8 (Abbot RD, Kalousdian S,)]TJ
0 Tc 1.875 -1.25 Td
[(Kankel )17.8 (WB. Incidence of coronary heart disease and lipoprotein)]TJ
T*
[(cholesterol levels. )17.7 (The Framingham study)64.9 (. JAMA)-220.1 (1986;256:2835-8.)]TJ
-0.00011 Tc -1.875 -1.25 Td
[(20.)-625.1 (Zar JH. Biostatistical analysis. New )36.7 (Y)100 (ork: Prentice-Hall; 1996.)]TJ
T*
[(21.)-625.1 (W)79.7 (ard MM. Premature morbidity from cardiovascular and)]TJ
1.875 -1.25 Td
(cerebrovascular diseases in women with systemic lupus)Tj
0 Tc T*
[(erythematosus. )54.9 (Arthritis Rheum 1999;42:338-46.)]TJ
-0.00011 Tc -1.875 -1.25 Td
[(22.)-625.1 (Anderson )17.7 (TJ, Gerhard MD, Meredith IT)73.9 (, et al. Systemic nature of)]TJ
0 Tc 1.875 -1.25 Td
[(endothelial dysfunction in atherosclerosis. )54.8 (Am J Cardiol)]TJ
0 Tw T*
(1995;75:71-4.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(23.)-625.1 (Thorne )54.8 (A, Mullen MJ, Clarkson P)110.7 (,)-0.1 ( Ronald )54.8 (AE, Deanfield JE. Early)]TJ
0 Tc 1.875 -1.25 Td
(endothelial dysfunction in adults at risk from atherosclerosis:)Tj
T*
[(dif)17.8 (ferent responses to L-ar)17.8 (ginine. J )54.8 (Am Coll Cardiol 1998;32:1)36.8 (10-6.)]TJ
-1.875 -1.25 Td
[(24.)-625 (T)69.8 (akase B, Uehata )54.9 (A, )54.9 (Akima )17.8 (T)74 (, et al. Endothelial-dependent)]TJ
1.875 -1.25 Td
(vasodilation in coronary and brachial arteries in suspected coronary)Tj
T*
[(artery disease. )54.8 (Am J Cardiol 1998;82:1535-9.)]TJ
-0.00011 Tc -1.875 -1.25 Td
[(25.)-625.1 (Castelli )17.7 (WP)110.7 (. )17.7 (T)34.8 (riglyceride issue: a view from Framingham. )54.8 (Am Heart)]TJ
0 Tc 1.875 -1.25 Td
[(J 1986;1)36.9 (12:432-7. )]TJ
-1.875 -1.25 Td
[(26.)-625 (Castelli )17.7 (WP)110.8 (. Cardiovascular disease in women. )54.8 (Am J Obstet)]TJ
1.875 -1.25 Td
(Gynecol 1988;158:1553-60.)Tj
-0.00011 Tc -1.875 -1.25 Td
[(27.)-625.1 (Petri M, Spence D, Bone LR, Hochber)17.7 (g MC. Coronary artery)]TJ
1.875 -1.25 Td
(disease risk factors in the Johns Hopkins lupus cohort: prevalence,)Tj
0 Tc T*
(recognition by patients, and preventive practices. Medicine)Tj
0 Tw T*
(1992;71:291-302.)Tj
0.0249 Tw -1.875 -1.25 Td
[(28.)-625 (Berchtold P)110.8 (,)0.1 ( Jor)17.8 (gens )17.7 (V)129.2 (, Finke C, Ber)17.8 (ger M. Epidemiology of obesity)]TJ
1.875 -1.25 Td
(and hypertension. Int J Obes 1981;5 Suppl 1:1-5.)Tj
-0.00011 Tc -1.875 -1.25 Td
[(29.)-625.1 (Hartz )54.8 (AJ, Rupley DC, Kalkhof)17.7 (f RD, Rimm )54.8 (AA. Relationship of)]TJ
0 Tc 1.875 -1.25 Td
(obesity to diabetes: Influence of obesity level and body fat)Tj
T*
(distribution. Prev Med 1983;12:351-7.)Tj
-1.875 -1.25 Td
[(30.)-625 (Ko GTC, Chan JCN, Cockram CS. )17.7 (The association between)]TJ
1.875 -1.25 Td
(dyslipidaemia and obesity in Chinese men after adjustment for)Tj
-0.00011 Tc T*
[(insulin resistance. )54.8 (Atherosclerosis 1998;138:153-61.)]TJ
31.125 47.5 Td
[(31.)-625.1 (Lima DSN, Hatta F)79.7 (, Sato EI, Miranda Jr)54.8 (.F)79.7 (, Lima )17.7 (VC. Impaired)]TJ
0 Tc 1.875 -1.25 Td
(endothelium-dependent vasodilation in patients with systemic lupus)Tj
T*
[(erythematosus [abstract]. )54.8 (Arthritis Rheum 1997;40:162S. )]TJ
-1.875 -1.25 Td
[(32.)-625 (Belmont HM, Levartovsky D, Goel )54.9 (A, et al. Increased nitric oxide)]TJ
1.875 -1.25 Td
(production accompanied by the up-regulation of inducible nitric)Tj
T*
(oxide synthase in vascular endothelium from patients with systemic)Tj
T*
[(lupus erythematosus. )54.9 (Arthritis Rheum 1997;40:1810-6.)]TJ
-0.00011 Tc -1.875 -1.25 Td
[(33.)-625.1 (Anderson )17.7 (TJ, Uehata )54.8 (A, Gerhard MD, et al. Close relation of)]TJ
0 Tc 1.875 -1.25 Td
(endothelial function in the human coronary and peripheral)Tj
T*
[(circulation. J )54.9 (Am Coll Cardiol 1995;26:1235-41.)]TJ
-1.875 -1.25 Td
[(34.)-625 (Dhillon R, Clarkson P)110.8 (, Donald )54.9 (AE, et al. Endothelial dysfunction)]TJ
1.875 -1.25 Td
(late after Kawasaki disease. Circulation 1996;94:2103-6.)Tj
-1.875 -1.25 Td
[(35.)-625 (W)79.8 (oo KS, Chook P)110.8 (, Lolin )36.8 (YI, et al. Hyperhomocysteinemia is a risk)]TJ
1.875 -1.25 Td
(factor for arterial endothelial dysfunction in humans. Circulation)Tj
0 Tw T*
(1997;96:2542-4.)Tj
0.02499 Tw -1.875 -1.25 Td
[(36.)-625 (Adams MR, Robinson J, Mccredie R, et al. Smooth muscle)]TJ
1.875 -1.25 Td
(dysfunction occurs independently of impaired endothelium-)Tj
T*
[(dependent dilation in adults at risk of atherosclerosis. J )54.9 (Am Coll)]TJ
T*
(Cardiol 1998;32:123-7.)Tj
-1.875 -1.25 Td
[(37.)-625 (V)111.1 (aarala O, M\344ntt\344ri M, Manninen )17.7 (V)129.2 (, et al. )54.8 (Anti-cardiolipin)]TJ
1.875 -1.25 Td
(antibodies and risk of myocardial infarction in a prospective cohort)Tj
T*
(of middle-aged men. Circulation 1995;91:23-7.)Tj
-0.00011 Tc -1.875 -1.25 Td
[(38.)-625.1 (V)111 (aarala O, )54.8 (Alfthan G, Jauhiainen, M, Leirisalo-Repo M, )54.8 (Aho K,)]TJ
0 Tc 1.875 -1.25 Td
[(Palosuo )17.8 (T)74 (. Cross reaction between antibodies to oxidised LDL)-238.2 (and)]TJ
T*
(to cardiolipin in SLE. Lancet 1993;341:923-5.)Tj
-1.875 -1.25 Td
[(39.)-625 (V)111.1 (aarala O. )54.8 (Antiphospholipid antibodies and atherosclerosis. Lupus)]TJ
0 Tw 1.875 -1.25 Td
(1996;5:442-7. )Tj
0.02499 Tw -1.875 -1.25 Td
[(40.)-625 (Luliano BL, Pratico D, Ferro D, et al. Enhanced lipid peroxidation)]TJ
1.875 -1.25 Td
(in patients positive for antiphospholipid antibodies. Blood)Tj
0 Tw T*
(1997;90:3931-5.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(41.)-625.1 (Sorensen KE, Dorup I, Celermajer DS. Non invasive assessment of)]TJ
0 Tc 1.875 -1.25 Td
(endothelial vasomotor function. In: Born GVR, Schwartz CJ,)Tj
T*
[(editors. )17.8 (V)111.1 (ascular Endothelium. Physiology)64.9 (, pathology)64.9 (, and)]TJ
T*
(therapeutic opportunities. Stuttgart: Schattauer; 1997;373-84.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Lima, et al:)-250 (Endothelial dysfunction in SLE)]TJ
0 Tw 61.4375 -0.0313 Td
(297)Tj
ET
0 0 0 0 scn
/GS0 gs
104.25 59.08 407.5 -10.83 re
f*
0.5 w
104.25 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
98 0 obj
<>
endobj
116 0 obj
<>
endobj
67 0 obj
<>
endobj
62 0 obj
<>
endobj
64 0 obj
<>
endobj
92 0 obj
<>stream
HVpMg}9ބ(ysHInMzɽ*zʳ4 jL*kulR'j2YRzRk,߹ ~w{! B5~){`G騢`e)
X[T5G?s~"82+ߦ+Jn/l1{eGFYURwsLRmQEVJVxzP8yXGd`(>FW]! hwItq{@9N.
>GŨ:riV^|2vƢ duݰ'GbaXN1aV#&qT[#>N3/'ZD0T'EGK@,∧+xzQ2ϚE cĽ +✘,(g}fD_c4fawXh=1^ZVuRщ>1q'sWpUĈbKqX>ŭ,SvqZ'.RXgMQA➈)rUxxwD,z
*SsTΐ7PX#H$;d%{ (`"DDk[n8\D#ЄSD."_$/+!ȋJ2HRhw*fZ3ܮ+L̽^c1r'lʝ?'p
$F]ÓUӊ2*kŪgWT2
dWG`G>O$LEJ1jg=71}g(;ŮUf!Be=4o:AoJ];s{i;!iQKl]I/n2bwcWM@7J_/BE}iƧPѹP\?ZZh4|Zl8⾇Phmff9S6ڠ;`Tf
c_6r-[QT2fcjdg2`k?ؚGqbfTO븄~H?ꒈ:I;Kezr^2o+E?kQml{䢼V+Eq^&s[=HHT@FlԐ0F 'qxؘ([\WykixYc5*[Ǫ㨱mP_lٺx:3ȟ|3XCʶb眨6~s'Re9pȜg\ǑdK<Ʒs{ٓ~$f)]uAΛqHi"0l6SM'~F?cJyBG^*OX+z\=|e,ˀX c,c#lZF8QMbZC
0I(an$8(lA=@ ̀G$3Nôzv%
idҜٽgEǯZ}nCOUKsE^bՇ#lGh-wR(#.tH`x^5xw^~wr;Z:X{`}Q9&}B
7x Z[wqoyERP>m=ۥy>dQy=D2ru(1A\
[; 7kR{gC[@*AZX+akgf>r#dipQhxUȻR>2th)C~2Hd=&0Q|
Dk]! l
`U> B~
`VH@BzL
*M4`T N!{ *@] jP)d )SJ#=fVTm'x?zv\ll
pUpmLdx].^pkdo@X k40W'p=SʬԉW'ՉkD_S'*d+W{EW/<^gW>s2r,)4>K'ȯf)QTs O&'W_KWFÕ ?W WDëaPwi'i7"7wlj!<$JCEњմZQ
UgErcIEhavS~/һ''J4)j_yrB2Iz#V4_j(.$#^d0I;Vt I{yy
~{6$x
vWj؛>zu]$]M_^97>^ybҐ{@Vt;?Y+[q7&g4Lqn=̑lA=5i3S| WMG#y o傼D@g L:.MgtZZG`_ؕ8 @fZf4{±`AuNr >> o r i{ gb7ٙjIR>ҕ*uN^M| CHavp;t8:ʲ`^J?ׇw\4\
tB8~dN9AfyBSkx~ً]-X!j.`g1 EcAˋc6 Y;h+8
!?2s$inRha@#ۑd;M2H?hy)OP"IpJ$E)^/Pj22,nܔ4$\4&͵`?;|s.҆pmٚrJzBm7jdSA+0UHn&CݯU<!VTAe[</M;_yהwMQ]g9)٫YhdPX-FNnpJ BSDLY}?qֆX$̮b awd
Wfd?z~,lkxɴQMgw#O\&aJ'6ՠڌA,E`o?l6R9v`O{y]fGS[+pFiy|5,}W>&P6B}IċJZti%JEd@;3Zysßz b4k^JWCE
գ:-hqЌoθa֚Spe%>^蟩IU6c=e9S"Ԋ[g۬77{
.Q2fɞ[jYKH[;y[nrيh.·O_&w~j}+8~ϫnMخ&3Zڕ,je+ْ,ْma2^.H)3#I ()q 3mZBi 8Ą:mR$#i'DŤidAi'3ݷ:F~UTO aD [
noBi)(E.ui&WrIi2 5Rm]N-%i@y(BmB K£v,Lͻ66Ġ*eĵD_(f8Ёab3`3)Xfiً͜PdPjviBA_tCezvRt!VUҁ>t^Y0)wR0LeҪLs!X2K.-].
5eVvAe5$Q`&ƊHQώ]hΡ{fįE\cNIF5Egh'%䬭{zPGV
طdq.+[SGWu_Tu}g
\/|jtLȳ :#8ψT%5C˛!f98H(1CeCfFB:YK6hqWVEYd<*&
atw*c^G-NhAl[qU3
^xܾZ/_}SPjL}; XjP{ŗo-u9V5s
Tyq휞Y4𩞎H]oGE!e?#ea0VaF(
a2zH$uz0dAE+V0ZaT(86<:L@ŴO%МJd4$bru& TU 2xHI!1K%_vYO\e)zD__anC3*9z 5rBaPMZ,
U0?,W&9Ӳ%iI:Elada!1ua"DsT+9pT׀}q@zte]NhkrCC9<9<&/
<#/&jWR*O٧9ZLseM얎L7L7qH*N%/Mt"R,kQ~|&ʰ)T&iL8S*%Q
Y^}NY1$}obͧۘdc?6uu[kmz?:h5Mvtnd]b2-k$5FTkZt2c)85!cɬ(/7jiIXd&d&u[D!zՂc$ИӉ&(@m6R@%?V'/.<ں-i
X;CuPwX.J[2V0j(M1m{54p1!TPw2.7Dpda7Sy3L8%~13΄{O
PPT^BWQdnnS#
lĺ5[<ݥ]85@>Ԋ}k`sկudή%-ڲrƃ]zJ <y^Xmv[e7xc2}Ei]>qzǣZ0N:eޓޅ"1M]]K峸IFPQDcxx1.ER
8f6v]$K@?݅^ЅXo_
2Mϵw_"-`sІi\1qqs7p7vO.nThÉ(C<qPnVុG<Kot%~o$p-d>.>o6
#6vqUCP,@^ǿ)6`xcŏ5ɛݝnFww|}Kod=Ƀ|K{Vo4UjĦ@2QM/{
L#lVTF}m
QJ>lI==jRκFM]0uCQ^X<~ۑCEy.)8ܝ91A
)%̄˱j#h/l@cpU$#IŠ![$4bٍ=Cv6qa߷};|wvb_lßJ@CB|ZU
cL6}*kQ
JLZvSBR*UQ6WhGN x;=kK;3_&i{CW&ko@xivf?kv?ΎvsrhdV;?RC(dn뻎@5=uG7
wÐu߷pFvmb6d橕`f=k2DZ~&